Table 1.
Characteristics of randomized trials on CDSS effect on BP or LDL cholesterol
| Author, year of publication | Superiority/ Non-inferiority | Inclusion period | Follow up | Guideline adhered | Country | Type of practice | Prevention: primary, secondary or both | Number of participants | Age (mean (sd) or median (range) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CDSS | Usual Care | CDSS | Usual Care | ||||||||
| Patients with an indication for CVRM | |||||||||||
| Anchala et.al, 2015 [65] | Superiority | Aug 2011- March 2012 | 12 months | NR | India | PCP | Primary | 840 | 783 | NR *** | NR |
| Hicks et al, 2008 [66] | Superiority | July 2003 – Feb 2005 | 12 months | JNC VI + VII | USA | PCP | Both (*) | 786 | 1048 | 64 | 61 |
| Montgomery et.al, 2000 [67] | Superiority | Sept 1996 – Sept 1998 | 12 months | NR | UK | PCP | Both (1–17% secondary) | 229 | 157 | 71 (6) | 71 (5) |
| Roumie et. al, 2006 [68] | Superiority | July 2003 – Dec 2003 | 6 months | JNC-VII | USA | Hospital/PCP | Both (*) | 547 | 324 | 65.5 (12.0) | 65.1 (11.9) |
| Eaton et.al, 2011 [69] | Superiority | Oct 2004 - May 3005 | 12 months | ATP III | USA | PCP | Both (*) | 2000 | 2105 | 46.7 ()6.3) | 46.4 (8.4) |
| Gill et.al, 2009 [70] | NR | Nov 2005 – Oct 2006 | 12 months | ATP III | USA | PCP | Both (**) | 26,696 | 37,454 | NR *** | NR |
| Lester et al, 2006 [71] | Superiority | July 2003 – July 2004 | 12 months | NR | USA | PCP | Secondary | 118 | 117 | 64.3 (14.5) | 62.4 (13.3) |
| Patients with type II diabetes | |||||||||||
| Ali et.al, 2016 [72] | Superiority | Jan 2011 – June 2012 | 24–36 months | ADA | India and Pakistan | Outpatient clinics | Both (6.8–39.4% secondary | 575 | 571 | 54.2 (9.2) | 54.2 (9.2) |
| Cleveringa et.al, 2008 [73] | Non- inferiority | March 2005 – Aug 2007 | 12 months | Dutch CVRM | NL | PCP | Both (47.1 and 63.3% secondary) | 1699 | 1692 | 65.2 (11.3) | 65.0 (11.0) |
| Glasgow et.al, 2005 [74] | Superiority | 2001–2002 | 12 months | NR | USA | PCP | Both (*) | 379 | 354 | 62 (1.4) | 64 (1.3) |
| Grant et.al, 2008 [75] | Superiority | July 2005 – Sept 2007 | 12 months | NR | USA | PCP | NR | 126 | 118 | 58.8 (10.1) | 53.3 (12.3) |
| Holbrook et.al, 2009 [76] | Superiority | 2002–2003 | 5.9 months (mean) | American/ Canadian Diabetes Association | Canada | PCP | Both (5.5–19% secondary) | 253 | 258 | 61.0 (13.1) | 60.5 (11.9) |
| Ilag et.al, 2003 [77] | Superiority | Oct 1999 – Sept 2000 | 2 years | NR | USA | University affiliated PCP | NR | 83 | 71 | 59 (14) | 59 (120 |
| Maclean et.al, 2009 [78] | Superiority | June 2003 – Jan 2005 | 2 years | NR | Canada | PCP with hospital based clinical laboratories | NR | 3886 | 3526 | 62.4 (19–99) | 63.5 (18–97) |
| Mathers et.al, 2012 [79] | Superiority | 2008–2011 | 12 moths | NICE | UK | PCP | Both (3.2–31.1% secondary) | 95 | 80 | 66 (39–82) | 62 (42–87 |
| Meigs et.al, 2003 [80] | Superiority | May 1998 – April 1999 | 12 months | NR | USA | Hospital based internal medicine clinic | Both (52.4–50.9% secondary) | 307 | 291 | 68 (12) | 67 (12) |
| O’Connor et.al, 2011 [81] | NR | Oct 2006 – May 2007 | 6 months | NR | USA | PCP | Both (11.5–23.4% secondary) | 1194 | 1362 | 57.0 (10.7) | 57.5 (10.1) |
* distributions not reported; ** only specified categories of cardiovascular risk (from total study population: 18.6% high risk; 16.4 medium risk, 65% low risk); *** Presented percentages per age category, no overall mean/median age
NR not reported, RCT randomized controlled trial, PCP primary care practice, USA United States of America, UK United Kingdom, NL The Netherlands, JNC Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, ATP III Adult Treatment Panel III, ADA American Diabetes Association, NICE the National Institute for health and Care Excellence. * Superiority although not powered for within site variation